psmarketresearch1’s blog

All about market research update

Hodgkin’s Lymphoma Therapeutics Pipeline Analysis 2017 - Collaboration and Other Developments

The Hodgkin’s lymphoma therapeutics pipeline is expected to witness considerable growth in the coming years as the researchers are making novel drug delivery system for the treatment for cancer. The government agencies such as National Cancer Institute and American Cancer Society are supporting the growth of the Hodgkin’s lymphoma (HL) therapeutics pipeline by providing funding, designations and grants for speeding up the drug development process. High prevalence of cancer, increasing awareness regarding cancer treatment, technological advancements and high demand for safe and effective medication are driving the growth of the Hodgkin’s Lymphoma therapeutics pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/hodgkins-lymphoma-therapeutics-pipeline-analysis

 

Hodgkin lymphoma (HL) or Hodgkin’s disease is an uncommon cancer of the lymphatic system, such as lymph nodes. The lymphatic system is made up of a network of vessels and glands that spread throughout the body. The vessels of lymphatic system known as lymphocytes carrying clear fluid known as lymph, contains lymphocytes (white blood cells that help combat infection). The lymphatic is a part of the human body’s immune system. In Hodgkin’s lymphoma, the patient experiences a painless swelling in a lymph node, usually in the neck, armpit or groin.

 

Ono Pharmaceuticals and Bristol-Myers Squibb are in the process of developing Opdivo for the treatment of Hodgkin’s disease. Seattle Genetics has developed ADCETRIS (brentuximab vedotin) as an antibody drug conjugate for Hodgkin’s disease. Merck & Co., Inc. has also developed Keytruda for the treatment of Hodgkin’s lymphoma. Though, major companies are developing promising drugs for Hodgkin’s lymphoma treatment, the new entrants are facing the challenge of fulfilling the relapsed or refractory (R/R) Hodgkin’s lymphoma patients’ unmet needs, and of bringing a reduction in the adverse effects of current treatments in the long term, thereby improving patients’ overall survival.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/hodgkins-lymphoma-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of Hodgkin’s lymphoma therapeutics include Bristol-Myers Squibb Co., Merck & Co. Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Affimed Therapeutics AG, Aeterna Zentaris Inc., Incyte Corporation, and 4SC AG.